Hormonal Regulation of Body Weight Maintenance
12 januari 2018 bijgewerkt door: Professor Joachim Spranger, Charite University, Berlin, Germany
The investigators here propose to perform a collaborative clinical research effort including a randomized controlled trial investigating the mechanisms of weight maintenance and their relation to a lifestyle intervention in children, adolescents and adults.
The detailed investigation and analysis of the variability and dynamics of the endocrine circuits responding to a negative energy balance and weight loss will be accompanied and enhanced by specific clinical projects targeting peripheral and central-nervous aspects of hormonal counter-regulation after weight loss.
Mechanisms of endocrine counter-regulation and potential therapeutic approaches will be studied.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
286
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Berlin, Duitsland, 12200
- Charité
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
10 jaar tot 90 jaar (Kind, Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- BMI > 27 kg/m2 (adults)
Exclusion Criteria:
- weight loss of more than 5kg in the last 2 months
- pregnancy, breastfeeding
patients with:
- severe heart failure
- impaired hepatic or renal function
- anaemia
- disturbed coagulation (biopsies will not be taken in those subjects)
- infection, malabsorption
- severe hypertension
- cancer within the last 5 years
- eating disorders or any other psychiatric condition that would interact with the trial intervention
- any other endocrine disorder
- changes of smoking habits or diets within the last 3 months prior to study inclusion
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: placebo
Placebo
|
geen tussenkomst, alleen opvolging
|
|
Experimenteel: lifestyle intervention
After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
|
After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
BMI will be assessed during lifestyle intervention in (1) children and adolescents and (2) adults vs. placebo
Tijdsspanne: 21 months
|
BMI (kg/m2) will be analyzed after intentional weight loss in two comparable parts of a randomized controlled trial including (1) children and adolescents and (2) adults.
Therefore effects of a multimodal lifestyle intervention will be compared to placebo.
|
21 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Evaluation of leptin during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of leptin at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of leptin during follow up
Tijdsspanne: 48 months
|
Measurement of leptin during follow up until the 48 months
|
48 months
|
|
Evaluation of catecholamines during follow up
Tijdsspanne: 48 months
|
Measurement of catecholamines during follow up until the 48 months
|
48 months
|
|
Evaluation of catecholamines during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of catecholamines at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of cortisol during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of cortisol at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of cortisol during follow up
Tijdsspanne: 48 months
|
Measurement of cortisol during follow up until the 48 months
|
48 months
|
|
Evaluation of glucagon-like peptide 1 (GLP1) during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of GLP1 at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of GLP1 during follow up
Tijdsspanne: 48 months
|
Measurement of GLP1 during follow up until the 48 months
|
48 months
|
|
Evaluation of glucose-dependent insulinotropic polypeptide (GIP) during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of GIP at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of GIP during follow up
Tijdsspanne: 48 months
|
Measurement of GIP during follow up until the 48 months
|
48 months
|
|
Evaluation of thyroid hormones during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of thyroid hormones at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of thyroid hormones during follow up
Tijdsspanne: 48 months
|
Measurement of thyroid hormones during follow up until the 48 months
|
48 months
|
|
Evaluation of insulin during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of insulin at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of insulin during follow up
Tijdsspanne: 48 months
|
Measurement of insulin during follow up until the 48 months
|
48 months
|
|
Evaluation of insulin-like growth factor 1 (IGF1) during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of IGF1 at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of IGF1 during follow up
Tijdsspanne: 48 months
|
Measurement of IGF1 during follow up until the 48 months
|
48 months
|
|
Evaluation of natriuretic peptide during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18
|
Measurement of natriuretic peptide at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of natriuretic peptide during follow up
Tijdsspanne: 48 months
|
Measurement of natriuretic peptide during follow up until the 48 months
|
48 months
|
|
Evaluation of blood pressure during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Measurement of blood pressure at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
Evaluation of free fatty acids (FFAs) during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Measurement of FFAs at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
Evaluation of respiratory coefficient during lifestyle intervention
Tijdsspanne: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Measurement of respiratory coefficient at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
Measurement of messenger ribonucleic acid (mRNA) changes in adipose and skeletal muscle before (T-3), after weight loss (T0) and after as well as after 12 months randomized lifestyle intervention (or placebo)
Tijdsspanne: month -3, month 0, month 12
|
Measurement of systemic and tissue specific changes in adipose tissue and skeletal muscle using RNA sequencing (counts)
|
month -3, month 0, month 12
|
|
Measurement of insulin sensitivity
Tijdsspanne: month -3, month 0, month 12
|
Measurement of systemic and tissue specific changes in adipose and muscle insulin sensitivity using hyperinsulinemic clamp (mg•kg-1•min-1/(mU•L-1)) before (T-3), after weight loss (T0) and after as well as after 12 months randomized lifestyle intervention (or placebo)
|
month -3, month 0, month 12
|
|
Prediction of body weight regain
Tijdsspanne: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on long-term course of BMI (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of insulin sensitivity
Tijdsspanne: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on insulin sensitivity (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of energy expenditure
Tijdsspanne: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on energy expenditure (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of muscle mass
Tijdsspanne: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on muscle mass (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of fat mass
Tijdsspanne: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on fat mass (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
BMI course after a lifestyle intervention in (1) children and adolescents and (2) adults vs. placebo
Tijdsspanne: month 24, month 36, month 48
|
BMI (kg/m2) after the randomized control trial (RCT) (18 months) will be analyzed up to 48 months.
|
month 24, month 36, month 48
|
|
changes of fatty acids during the intervention
Tijdsspanne: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Analysis of fatty acids at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
changes acylcarnitines
Tijdsspanne: month -3, month 0
|
Analysis of acylcarnitines at baseline and after 3 months of weight loss
|
month -3, month 0
|
|
changes acylcarnitines
Tijdsspanne: month 12, month 18, month 24, month 36, month 48
|
Analysis of acylcarnitines after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month 12, month 18, month 24, month 36, month 48
|
|
body composition
Tijdsspanne: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Whole body fat mass (kg, %) will be measured at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Medewerkers
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Li L, Soll D, Leupelt V, Spranger J, Mai K. Weight loss-induced improvement of body weight and insulin sensitivity is not amplified by a subsequent 12-month weight maintenance intervention but is predicted by adaption of adipose atrial natriuretic peptide system: 48-month results of a randomized controlled trial. BMC Med. 2022 Jul 28;20(1):238. doi: 10.1186/s12916-022-02435-9.
- Soll D, Gawron J, Pletsch-Borba L, Spranger J, Mai K. Long-term impact of the metabolic status on weight loss-induced health benefits. Nutr Metab (Lond). 2022 Mar 28;19(1):25. doi: 10.1186/s12986-022-00660-w.
- Li L, Spranger L, Stobaus N, Beer F, Decker AM, Wernicke C, Brachs S, Brachs M, Spranger J, Mai K. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss-weight maintenance. Nutr Diabetes. 2021 Oct 5;11(1):31. doi: 10.1038/s41387-021-00174-z.
- Li L, Spranger L, Soll D, Beer F, Brachs M, Spranger J, Mai K. Metabolic impact of weight loss induced reduction of adipose ACE-2 - Potential implication in COVID-19 infections? Metabolism. 2020 Dec;113:154401. doi: 10.1016/j.metabol.2020.154401. Epub 2020 Oct 13.
- Brachs S, Polack J, Brachs M, Jahn-Hofmann K, Elvert R, Pfenninger A, Barenz F, Margerie D, Mai K, Spranger J, Kannt A. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity but Does Not Affect Glucose Tolerance. Diabetes. 2019 Mar;68(3):527-542. doi: 10.2337/db18-0780. Epub 2018 Dec 14.
- Mai K, Li L, Wiegand S, Brachs M, Leupelt V, Ernert A, Kuhnen P, Hubner N, Robinson P, Chen W, Krude H, Spranger J. An Integrated Understanding of the Molecular Mechanisms of How Adipose Tissue Metabolism Affects Long-term Body Weight Maintenance. Diabetes. 2019 Jan;68(1):57-65. doi: 10.2337/db18-0440. Epub 2018 Nov 2.
- Bau AM, Ernert A, Krude H, Wiegand S. Hormonal regulatory mechanisms in obese children and adolescents after previous weight reduction with a lifestyle intervention: maintain - paediatric part - a RCT from 2009-15. BMC Obes. 2016 Jun 10;3:29. doi: 10.1186/s40608-016-0110-8. eCollection 2016.
- Brachs M, Wiegand S, Leupelt V, Ernert A, Kintscher U, Jumpertz von Schwarzenberg R, Decker AM, Bobbert T, Hubner N, Chen W, Krude H, Spranger J, Mai K. ANP system activity predicts variability of fat mass reduction and insulin sensitivity during weight loss. Metabolism. 2016 Jun;65(6):935-43. doi: 10.1016/j.metabol.2016.03.013. Epub 2016 Apr 7.
- Weygandt M, Mai K, Dommes E, Ritter K, Leupelt V, Spranger J, Haynes JD. Impulse control in the dorsolateral prefrontal cortex counteracts post-diet weight regain in obesity. Neuroimage. 2015 Apr 1;109:318-27. doi: 10.1016/j.neuroimage.2014.12.073. Epub 2015 Jan 7.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 januari 2010
Primaire voltooiing (Werkelijk)
1 december 2015
Studie voltooiing (Werkelijk)
1 januari 2016
Studieregistratiedata
Eerst ingediend
17 februari 2009
Eerst ingediend dat voldeed aan de QC-criteria
24 februari 2009
Eerst geplaatst (Schatting)
25 februari 2009
Updates van studierecords
Laatste update geplaatst (Werkelijk)
17 januari 2018
Laatste update ingediend die voldeed aan QC-criteria
12 januari 2018
Laatst geverifieerd
1 januari 2018
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EA2/017/09
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .